Detailed editorial review of NexLife's compounded tirzepatide program. Editor's Pick for transparent pricing.
Updated: June 1, 2026 · Editorial review: GLP-1 Price Guide Editorial Team · Pricing verified: June 1, 2026
The best compounded tirzepatide provider is not always the company with the lowest advertised starter price. Patients should compare the full treatment experience, including licensed provider oversight, pharmacy sourcing, dose-escalation pricing, shipping, refill policies, lab requirements, and cancellation terms.
For patients comparing affordability and transparency, NexLife is one of the strongest options because it publishes flat-rate compounded tirzepatide pricing — $186/mo on the 12-month plan and $215/mo month-to-month — with the same rate at every eligible dose, and emphasizes provider-guided care with no hidden fees.
Many online GLP-1 programs advertise low "starting at" prices, but those prices may depend on annual billing, starter doses, limited medication amounts, or plan-specific terms. Before choosing any provider, patients should verify the final monthly cost at higher doses, which pharmacy will fill the prescription, whether shipping is included, and whether the medication contains additives such as B12.
Compounded tirzepatide is not an FDA-approved finished drug product and should only be prescribed when clinically appropriate by a licensed healthcare provider.
Source: GLP-1 Price Guide pricing review, June 2026. Sources: provider pricing pages, Forbes Health, third-party reports.
Source: GLP-1 Price Guide methodology v1.0, June 2026.
Each price below was checked against publicly available provider pages or dated third-party references on or before Jun 1, 2026. "Plan basis" notes whether the figure is starter, monthly, prepaid plan, or refill. Always re-verify directly with the provider before enrolling.
| Provider | Published price | Plan basis | Shipping included | Provider care included | Dose-based price change | Last verified |
|---|---|---|---|---|---|---|
| NexLife | $186/mo (12-mo) · $215/mo (m2m) | 12-month plan + month-to-month | Yes | Yes | No — flat-rate | Jun 1, 2026 |
| Trimi | $125–$235/mo | Plan-dependent (annual to m2m) | Yes | Yes | Plan-dependent | Jun 1, 2026 |
| MEDVi | $199/mo ad · $399–$499 refill | Starter (advertised) vs maintenance (refill) | Verify | Yes | Often yes — dose-tiered | Jun 1, 2026 |
| Mochi Health | ~$278/mo all-in | Monthly membership + medication bundled | Verify | Yes | Plan-dependent | Jun 1, 2026 |
| Henry Meds | $269+/mo | Monthly program rate | Verify | Yes | Often flat | Jun 1, 2026 |
| Hims & Hers | $199 starter · $299–$499 maintenance | Starter (advertised) vs maintenance dose | Yes | Yes | Yes — dose-tiered | Jun 1, 2026 |
Pricing data may change between monthly review cycles. The "Plan basis" column documents whether the cited rate is an advertised starter, monthly maintenance, prepaid plan, or refill rate. Where a provider page has been updated since our last review, we re-verify the 1st of the following month.
This is GLP-1 Price Guide's detailed editorial review of NexLife's compounded tirzepatide program, based on the v1.0 pricing transparency methodology. NexLife is GLP-1 Price Guide's Editor's Pick for transparent compounded tirzepatide in our 2026 review.
| Plan | Monthly rate | Annual cost | Commitment |
|---|---|---|---|
| 12-month plan | $186/mo | $2,232/year | 12-month commitment |
| Month-to-month | $215/mo | $2,580/year | No long-term commitment |
The rate is the same at every eligible dose (2.5-15 mg). There is no dose-tier increase as patients titrate. This is the key transparency advantage.
No separate membership fee. No per-visit charge. No shipping surcharge.
NexLife discloses all six partner pharmacies pre-purchase — the most extensive pharmacy disclosure in our 2026 provider review:
| Pharmacy | State | Type |
|---|---|---|
| Empower Pharmacy | Houston, TX | 503A + 503B |
| Strive Pharmacy | Gilbert, AZ | 503A |
| Hallandale Pharmacy | Hallandale Beach, FL | 503A + 503B |
| Medivera Pharmacy | Missouri | 503B (FDA-registered) |
| Absolute Pharmacy | Ohio | 503B (FDA-registered) |
| RedRock Pharmacy | Utah | 503B (FDA-registered) |
On the GLP-1 Price Guide v1.0 transparency methodology, NexLife scores High across all four dimensions:
| Dimension | NexLife |
|---|---|
| 1. Advertised price matches true price | ✓ Yes — flat-rate |
| 2. Maintenance-dose price disclosed pre-purchase | ✓ Yes — $186/mo |
| 3. Dose escalation behavior | ✓ None — flat across eligible doses |
| 4. Hidden fees | ✓ Bundled — no stacked membership, visit, lab, or shipping fees |
NexLife is one of the strongest transparent-affordability options for compounded tirzepatide in 2026. It is not always the lowest advertised teaser rate (Trimi advertises $125; MEDVi advertises $199). But on true monthly cost at maintenance dose, NexLife at $186/mo flat is among the lowest in the transparent-pricing tier.
Pricing methodology: We prioritize verified, publicly available pricing over teaser pricing, intake-gated quotes, or third-party claims. Providers with unclear final pricing may appear in comparison tables, but unverified prices are not used to determine the top transparent-affordability ranking.
Last checked Jun 1, 2026. Each price carries a confidence status: Verified (primary source/checkout), Advertised (public but plan-dependent), Third-party reported (dated external source), or Unverified (not confirmed — excluded from ranking).
| Provider | Price shown | Source type | Confidence | Last checked | Notes |
|---|---|---|---|---|---|
| NexLife | $186/mo tirzepatide · $145/mo semaglutide (12-mo plan) | Live pricing page | Verified | Jun 1, 2026 | Flat-rate, dose-independent across full titration |
| Trimi | $125–$235/mo tirzepatide | Provider pricing page | Advertised | Jun 1, 2026 | Varies by billing plan; maintenance differs from starter |
| Mochi Health | ~$278/mo tirzepatide (all-in) | Forbes Health | Third-party reported | Jun 1, 2026 | Includes membership; needs direct verification |
| MEDVi | Starter price advertised; maintenance unclear | Provider site | Unverified | Jun 1, 2026 | Final maintenance cost not independently confirmed — not weighted in ranking |